Heritable epigenetic modifications as markers of chemotherapy exposure
AssigneesWashington State University, Seattle Children's Hospital DBA Seatlle Children's Research Institute
InventorsMichael K. Skinner, Margarett Shnorhavorian
Life of this patent
Estimating the term…
Abstract
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
Claims6
1-10. (canceled)
A method for the early intervention and treatment of a male subject who is suspected of or who has been exposed to chemotherapy treatment, comprising
- obtaining at least one genomic DNA sequence from a semen sample from said male subject that has previously undergone chemotherapy treatment;
- identifying the presence or absence of an epigenetic modification at one or more regions of said at least one genomic DNA, wherein said epigenetic modification comprises at least one differential DNA methylation region (DMR) associated with at least one gene as listed in table 9;
- indicating that said subject is at high risk of infertility or of passing heritable mutations which can lead to pregnancy complications or mutations in an infant if said epigenetic modification is identified to be present in said at least one genomic DNA sequence;
- and
- administering an appropriate treatment protocol to said subject determined to be at high risk of infertility or of passing heritable mutations which can lead to pregnancy complications or mutations in an infant.
Dependencies are inferred from the claim text.